Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by jimmyhorizonon Jul 26, 2022 2:54am
185 Views
Post# 34850109

RE:RE:RE:RE:Remember this

RE:RE:RE:RE:Remember this
biorun wrote: I am just saying nobody should use a high upfront payment figure without explanation and if you want to go back to that $90 million upfront declaration, as soon as Attila said that number, the video was immediately taken down., not too long after he was "gone". I suspect that he spoke out of step here.


Wexie, you know that this is not true. Yes upfront was 90m and not 100m (look how easy it is to admit a mistake). the following figures were used in the investor presentations over the period of at least one year

Investor-presentation Jan 31. 2016:

2016E - Upfront payment of $90M in Q2 (**)

2019E - Milestone payment of $98M (**)

 

2020E - Ongoing royalties totaling $715M (**)


Investor-presentation July 8, 2016

2016E - Upfront payment of $90M in Q3 (**)

2019E - Milestone payment of $98M (**)

2020E - Ongoing royalties totaling $715M (**)

Investor-presentation Nov 1, 2016

2016E - Upfront payment of $90M in Q4 (**)

2019E - Milestone payment of $100M (**)

2020E - Ongoing royalties totaling $1B (**)

Wexi, i'm ready to put the past behind us, but that requires that we stop getting screwed. I recognize that we are being fooled less.

 


 

<< Previous
Bullboard Posts
Next >>